NLRP3 and Cognitive impairment: Recent evidence has shown a direct correlation between NLRP3 inflammasome activation and cognitive impairments in AD [7], suggesting that modulating NLRP3 inflammasome activation to reduce pyroptosis may offer new therapeutic targets for AD treatment.